Trial reportBMC medicine2025
Efficacy, safety, and exploratory biomarker analysis of envafolimab plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer: a prospective, single-arm, phase II trial.
Trial report in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Envafolimab - novel anti-PD-1/PD-L1 antibody in cancer treatment.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtensive-stage small cell lung cancer (ES-SCLC) is characterized by a high risk of malignancy and a poor prognosis. This trial aimed to evaluate the efficacy and safety of envafolimab plus chemotherapy as a first-line treatment for ES-SCLC.
methodsThis prospective, single-arm, phase II trial was conducted at the Fifth Medical Center of Chinese PLA General Hospital. Eligible patients with histologically or cytologically confirmed ES-SCLC were consecutively enrolled. Patients were given four cycles of carboplatin (area under the curve of 5-6 mg/mL/min, day 1 of each cycle) and etoposide (80-100 mg/m
resultsBetween October 2021 and November 2022, a total of 32 patients were enrolled in this trial. A total of 32 patients were included in the safety analysis, and 31 patients were included in the efficacy analysis. As of the data cutoff (September 15, 2024), the median follow-up was 27.7 months (IQR, 22.6-NA). The objective response rate (ORR) was 87.1% (95% CI, 70.2-96.4%), and the disease control rate (DCR)was 100% (95% CI, 88.8-100%). The median duration of response (DoR) was 5.47 months (95% CI, 3.43-10 months). The median progression-free survival (PFS) was 6.43 months (95% CI, 4.83-7.67 months), and median overall survival (OS) was 20 months (95% CI, 14.7-NA). Treatment-related adverse events (TRAEs) of any grade were reported in 59.4% of patients, with grade ≥ 3 TRAEs reported in 15.6% of patients. No treatment-related deaths occurred. Additionally, findings from serum proteomic profiling demonstrated that specific immune-related proteins, including CCL3, CXCL10, HGF, and CXCL8, might be correlated with shorter survival and worse clinical outcomes.
conclusionsEnvafolimab combined with chemotherapy as a first-line treatment for ES-SCLC yielded favorable clinical efficacy with a manageable safety profile, indicating that it may be a promising treatment modality.
trial registrationThis trial was registered at chictr.org.cn (ChiCTR2100044981).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.